Nusinersen
- PDF / 169,185 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 84 Downloads / 150 Views
1 S
Thrombocytopenia: case report In a retrospective study of 38 patients conducted in Hungary between April 2018 and December 2019, 1 patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with nusinersen for spinal muscular atrophy. The patient, who had a history of spinal muscular atrophy, underwent lumbar punctures and then intrathecal nusinersen injection was administered [dosage not stated]. During this period, the patient was sedated with gas in combination with an unspecified local anaesthetic agent. The patient completed the first 6 treatments of nusinersen and was assessed on day 307 of the treatment period. However, the patient developed mild and transient thrombocytopaenia during the treatment period [duration of treatment to reaction onset and outcome not stated]. Szabo L, et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. European Journal of Paediatric Neurology 27: 803502197 37-42, Jul 2020. Available from: URL: http://doi.org/10.1016/j.ejpn.2020.05.002
0114-9954/20/1822-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 19 Sep 2020 No. 1822
Data Loading...
